Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dreieich – page 39

1 481 clinical trials in Dreieich, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dreieich at a glance
1 481
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 481 trials in Dreieich

Open in trial search

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lufepirsen
  • Sponsor:Glaukos Corp.

Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ozunacogene parvec
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:AstraZeneca AB

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study on the Safety and Efficacy of a Hepatitis B Vaccine with Hepatitis B Surface Antigen (rDNA), MVA-HBVAC, and Mosaic HBcoreAg for Adults with Chronic Hepatitis B

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mva-Hbvac
  • Sponsor:Klinikum Der Universitat Munchen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dreieich

What the registry says about research in the country

01 Allergy Research

Clinical trials focusing on innovative treatments for allergic rhinoconjunctivitis, particularly targeting birch pollen and house dust mite allergies.

  • Birch Pollen Allergies
  • House Dust Mite Sensitivity
  • Immunotherapy Development

Research includes evaluation of subcutaneous immunotherapy treatments and novel allergoid formulations.

02 Pediatric Allergology

Dedicated studies examining the safety and efficacy of STALORAL® treatments in children and adolescents with seasonal allergies.

  • Child-Specific Treatments
  • Age-Appropriate Dosing
  • Safety Monitoring

Special focus on developing safe and effective treatments for young patients aged 5-17 years.

03 Respiratory Medicine

Comprehensive research into moderate to severe allergic conditions affecting the respiratory system, including asthma complications.

  • Combined Symptom Management
  • Therapeutic Efficacy
  • Long-term Treatment Outcomes

Studies evaluate both symptomatic relief and long-term disease modification approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.